Treatment of partial growth hormone insensitivity syndrome
US5646113A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 7, 1994 |
| Grant date | Jul 8, 1997 |
| Priority date | — |
| Expiry date | Apr 7, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/72
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering a dose of greater than 0.3 mg/kg/week of growth hormone, preferably growth hormone with a native human sequence, with or without an N-terminal methionine, to the patient. The patient is characterized as having a height of less than about -2 standard deviations below normal for age and sex, serum levels of high-affinity growth hormone binding protein and IGF-I that are at least 2 standard deviations below normal levels, and a serum level of growth hormone that is at least normal. In another such method, the same patient population is treated with an effective amount of IGF-I alone or in combination with an amount of growth hormone that is effective in combination with IGF-I.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.